普健生物（武汉）科技有限公司（AtaGenix）
Recombinant Human CD80 protein ,C- His Tag
- 1
- 产品信息
- 前沿进展（Frontier progress）
- 如何订购
- 说明书
概述（Summary）icon
英文全称
Recombinant Human CD80 protein ,C- His Tag
纯度（Purity）
>90% as determined by SDS-PAGE
内毒素（Endotoxin level）
<1.0 EU per μg of the protein as determined by the LAL method.
蛋白构建（Construction）
A DNA sequence encoding the human CD80(Met1~Asn242) was fused with the C-terminal His Tag
Accession #
P33681
表达宿主（Host）
Mammalian cells
种属（Species）
Homo sapiens (Human)
预测分子量（Predicted Molecular Mass）
28.52KDa
制剂（Formulation）
Supplied as solution form in PBS, pH7.5 or lyophilized from PBS, pH7.5.
运输方式（Shipping）
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
稳定性&储存（Stability &Storage）
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
复溶（Reconstitution）
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
电泳图（SDS-PAGE image）icon
背景（Background）icon
背景介绍
B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
分子别名（Alternative Names）
CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7
参考文献（References）
Pack, Bommireddy, Munoz, Patel, Bozeman, Dey, Radhakrishnan, Vartabedian, Venkat, Ramachandiran, Reddy, Selvaraj (2020) Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer Human vaccines & immunotherapeutics () 1-10
Triple-negative breast cancer (TNBC) afflicts women at a younger age than other breast cancers and is associated with a worse clinical outcome. This poor clinical outcome is attributed to a lack of defined targets and patient-to-patient heterogeneity in target antigens and immune responses. To address such heterogeneity, we tested the efficacy of a personalized vaccination approach for the treatment of TNBC using the 4T1 murine TNBC model. We isolated tumor membrane vesicles (TMVs) from homogenized 4T1 tumor tissue and incorporated glycosyl phosphatidylinositol (GPI)-anchored forms of the immunostimulatory B7-1 (CD80) and IL-12 molecules onto these TMVs to make a TMV vaccine. Tumor-bearing mice were then administered with the TMV vaccine either alone or in combination with immune checkpoint inhibitors. We show that TMV-based vaccine immunotherapy in combination with anti-CTLA-4 mAb treatment upregulated immunomodulatory cytokines in the plasma, significantly improved survival, and reduced pulmonary metastasis in mice compared to either therapy alone. The depletion of CD8+ T cells, but not CD4+ T cells, resulted in the loss of efficacy. This suggests that the vaccine acts via tumor-specific CD8+ T cell immunity. These results suggest TMV vaccine immunotherapy as a potential enhancer of immune checkpoint inhibitor therapies for metastatic triple-negative breast cancer.
1搜索商品：关键字搜索；分类导航搜索；产品联系：手机/微信同号：15972188750，座机：027-65279366（推荐 ！）
2产品选购：确定好产品信息与规格，向产品客服询问底价
3提交订单：向客服提交收货人信息，选择送货方式，支付方式，发票信息
4产品发货：发票随产品一起发送，耐心等待收货即可
质量保证：
所售产品均经过严格的质量检验，确保所供产品的技术指标与生产厂家的目录、说明书、质检报告上的描述一致，请放心选购。
质量与免责说明：
买方验收产品时，如发现产品短缺、不匹配、包装破损等情况，请保持产品原包装状态，并在收货七个工作日内，以书面方式向我司提出异议。逾期未提出异议视为合格。
买方保管产品时，应按照产品标签、说明书所示保管条件保存，如系保管不当导致产品质量问题，恕不受理。
买方使用产品时。如发现产品质量问题，应在使用初期提出，而非在使用完或快使用完时提出，以备我司回收产品，确认产品质量。如确属质量问题，我司负责调换或退货。发生索赔事宜，我司将在产品价格额度范围内酌情赔偿，恕不受理超出产品本身价值之部分。自收货之日起，超过三个月未反映产品问题，恕不退换。
我司所提供的产品仅限于专业人士的科学研究使用，不得用于临床诊断或者治疗，若有单位或者个人擅自改变我司产品用途，我司不承担任何责任。
- 服务咨询电话：027-87001869
- 产品咨询电话：027-65279366
- 邮箱：Info@atagenix.com[商务咨询] Sales@atagenix.com[订单咨询]
- 地址：武汉东湖新技术开发区神墩四路 666 号C栋
关注“普健生物”
微信公众号
普健生物（武汉）科技有限公司（AtaGenix） 鄂ICP备15005566号-1
Copyright © 2024 Lawyer Theme All Rights Reserved
Copyright © 2024 Lawyer Theme All Rights Reserved